A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 652 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout July 29, 2021 A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... August 29, 2023 Prostate Cancer December 9, 2019 Do Cancer Survivors Have To Be Positive All the Time? Letting... November 10, 2021 Load more HOT NEWS CancerLand Bookshelf : Loosen EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib How Does CAR T-Cell Therapy Work in Treating Cancer? We’re asking scientists to tackle 9 of the toughest challenges in...
